Scientists at the Gladstone Institutes have defined for the first time a key underlying process implicated in multiple sclerosis.
Scientists at the Gladstone Institutes and the Stanford University School of Medicine have discovered how modifying a gene halts the toxic buildup of a protein found in nerve cells. These findings point to a potential new tactic for treating a variety of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease)—a fatal disease for which there is no cure.
Gladstone scientists have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)—a form of early-onset dementia that is similar to Alzheimer’s disease.
Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer’s-related impairments in an animal model of the disease.
Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, has received the Khalid Iqbal Lifetime Achievement Award for his exceptional contributions to Alzheimer's disease research.
Gladstone scientists participate in an international consortium that uses stem cell technology to tackle Huntington's disease
Scientists at the Gladstone Institutes have transformed skin cells into cells that develop into a neural network.
Scientists at the Gladstone Institutes have determined how specific circuitry in the brain controls not only body movement but also motivation and learning, providing new insight into neurodegenerative disorders such as Parkinson's disease—and psychiatric disorders such as addiction and depression.